BREAST CANCER

The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.

Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.

A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.

A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.

Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone.

Improvement in progression-free-survival was demonstrated across all relevant subgroups in patients with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.

Early findings from the DEBBRAH study suggest that fam-trastuzumab deruxtecan-nxki shows potential in treating patients with advanced HER2-positive, HER2-low breast cancer, including those with leptomeningeal carcinomatosis.

Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.

Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.

Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.

Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.

Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.

Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.

Prospective models show a drop in the cost of running sentinel lymph node assessments when artificial intelligence is used.

Adding ribociclib to endocrine therapy shows efficacy and tolerability for those with hormone receptor–positive, HER2-negative advanced breast cancer, even in older patients.

An experimental drug combination of inavolisib, palbociclib, and fulvestrant significantly improved progression-free survival in patients with HR-positive/HER2-negative PIK3CA-mutated breast cancer.

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.

A fast track designation has been granted to zotatifin with fulvestrant, and abemaciclib for adult patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.

In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.

In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.

In addition to the approval of capivasertib and fulvestrant, the FDA has granted approval to the FoundationOne® CDx as a companion diagnostic to identify patients with advanced HR-positive, HER2-negative advanced breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, William J. Gradishar, MD, discussed dosing and toxicity considerations related to elacestrant in metastatic breast cancer with participants.

The FDA has approved capivasertib with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.

In 2 separate, live virtual Case-Based Roundtable events, physicians from across the country discussed the treatment path from frontline therapy to second-line sacituzumab govitecan for patients with metastatic TNBC.

Following the FDA’s denial of a de novo classification request of ProSense, citing concerns about the choice of comparator group used in the ICE3 trial, IceCure is working to identify a more representative comparator group.

In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.